Journal article
Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation
Abstract
AIMS: The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial allowed patients who completed the trial receiving their assigned dabigatran 150 mg (D150) or 110 mg (D110) twice a day to continue into the Long-term Multicenter Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) trial. This permitted assessment of outcomes over a median of 4.6 and a maximum of 6.7 years, respectively.
METHODS AND …
Authors
Ezekowitz MD; Eikelboom J; Oldgren J; Reilly PA; Brueckmann M; Kent AP; Pogue J; Spahr J; Clemens A; Noack H
Journal
EP Europace, Vol. 18, No. 7, pp. 973–978
Publisher
Oxford University Press (OUP)
Publication Date
July 2016
DOI
10.1093/europace/euv312
ISSN
1099-5129